Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Aug 25:8:206.
doi: 10.3389/fnagi.2016.00206. eCollection 2016.

Combined Treatment with Amlodipine and Atorvastatin Calcium Reduces Circulating Levels of Intercellular Adhesion Molecule-1 and Tumor Necrosis Factor-α in Hypertensive Patients with Prediabetes

Zhouqing Huang  1 , Chen Chen  1 , Sheng Li  1 , Fanqi Kong  1 , Peiren Shan  1 , Weijian Huang  1
Affiliations

Combined Treatment with Amlodipine and Atorvastatin Calcium Reduces Circulating Levels of Intercellular Adhesion Molecule-1 and Tumor Necrosis Factor-α in Hypertensive Patients with Prediabetes

Zhouqing Huang et al. Front Aging Neurosci. .

Abstract

Objective: To assess the effect of amlodipine and atorvastatin on intercellular adhesion molecule (ICAM)-1 and tumor necrosis factor (TNF)-α expression, as endothelial function and inflammation indicators, respectively, in hypertensive patients with and without prediabetes.

Methods: Forty-five consecutive patients with hypertension, diagnosed according to JNC7, were divided into two groups based on the presence (HD group, n = 23) or absence (H group, n = 22) of prediabetes, diagnosed according to 2010 ADA criteria, including impaired glucose tolerance (IGT) and fasting glucose tests. All patients simultaneously underwent 12-week treatment with daily single-pill amlodipine besylate/atorvastatin calcium combination (5/10 mg; Hisun-Pfizer Pharmaceuticals Co. Ltd). Serum isolated before and after treatment from overnight fasting blood samples was analyzed by ELISA.

Results: In the HD and H groups after vs. before 12-week amlodipine/atorvastatin treatment, there were significantly (all P < 0.01) lower levels of ICAM-1 (3.06 ± 0.34 vs. 4.07 ± 0.70 pg/ml; 3.26 ± 0.32 vs. 3.81 ± 0.60 pg/ml, respectively) and TNF-α (78.71 ± 9.19 vs. 110.94 ± 10.71 pg/ml; 80.95 ± 9.33 vs. 101.79 ± 11.72 pg/ml, respectively), with more pronounced reductions in HD vs. H group (ICAM-1Δ: 1.01 ± 0.80 vs. 0.55 ± 0.64 pg/ml, respectively, P = 0.037; TNF-αΔ: 32.23 ± 14.33 vs. 20.84 ± 14.89 pg/ml, respectively, P = 0.011), independent of the blood pressure (BP) and cholesterol level reduction.

Conclusions: Amlodipine/atorvastatin improved endothelial function and inflammation, as reflected by lower circulating levels of ICAM-1 and TNF-α, more prominently in hypertensives with than without prediabetes. Starting statin treatment before overt diabetes in hypertensives might thus improve cardiovascular outcomes.

Keywords: amlodipine and atorvastatin calcium; endothelial dysfunction; hypertension; inflammation; intercellular adhesion molecule-1; prediabetes; tumor necrosis factor-α.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Comparisons of reductions in Blood pressure (BP) and blood lipid levels between study groups. All P > 0.05.
Figure 2
Figure 2
Comparison between serum levels of biomarkers before and after treatment. ¤P < 0.01, compared with baseline.
Figure 3
Figure 3
Comparisons between treatment-associated reductions in biomarker levels between the two study groups. §P = 0.037, §§P = 0.011, compared with HΔ.
See this image and copyright information in PMC

References

    1. American Diabetes Association . (2010). Standards of medical care in diabetes—2010. Diabetes Care 33, S11–S61. 10.2337/dc10-s011 - DOI - PMC - PubMed
    1. Ascer E., Bertolami M. C., Venturinelli M. L., Buccheri V., Souza J., Nicolau J. C., et al. (2004). Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. Atherosclerosis 177, 161–166. 10.1016/j.atherosclerosis.2004.07.003 - DOI - PubMed
    1. Chapman M. J., Sposito A. C. (2008). Hypertension and dyslipidaemia in obesity and insulin resistance: pathophysiology, impact on atherosclerotic disease and pharmacotherapy. Pharmacol. Ther. 117, 354–373. 10.1016/j.pharmthera.2007.10.004 - DOI - PubMed
    1. Charbonneau F., Anderson T. J., Title L., Jobin J., Poirier P., Huyhn T., et al. (2008). Modulation of arterial reactivity using amlodipine and atorvastatin measured by ultrasound examination (MARGAUX). Atherosclerosis 197, 420–427. 10.1016/j.atherosclerosis.2007.06.019 - DOI - PubMed
    1. Chobanian A. V., Bakris G. L., Black H. R., Cushman W. C., Green L. A., Izzo J. L., et al. (2003). Seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure. Hypertension 42, 1206–1252. 10.1161/01.HYP.0000107251.49515.c2 - DOI - PubMed